Precision Genomics Successfully Attends the LD Micro Conference
Ludwig Enterprises (OTC PINK:LUDG) announced a successful participation at the LD Micro Conference, showcasing its subsidiary, Precision Genomics. Dr. Marvin S. Hausman MD, recognized for his past successes in taking medical companies public, represented Precision Genomics and engaged in one-on-one meetings with major investment banks.
The company is preparing to file an S-1 with the SEC, aiming for a NASDAQ listing. Precision Genomics focuses on genomic testing to improve health outcomes, working on research related to Long Covid and other diseases.
- Successful attendance at the LD Micro Conference, leading to significant investor interest.
- Dr. Hausman's recognition and past experience enhance credibility and potential partnerships.
- Company preparing to file an S-1 with the SEC, indicating progress towards a NASDAQ listing.
- None.
Dr. Hausman has been continually requested for interviews.
LAS VEGAS, NV / ACCESSWIRE / November 7, 2022 / (OTC PINK:LUDG) Ludwig Enterprises with Precision Genomics, a wholly-owned subsidiary of Ludwig Enterprises, is pleased to announce our recent attendance at the LD Micro Conference was a success. LD Micro Conference is the premier event where investment banks, family offices, and the world's micro-cap companies meet for a week. The conference was attended for Precision Genomics by Dr. Marvin S. Hausman MD. Dr. Hausman was immediately recognized at the conference due to his extensive research and entrepreneurial experience, including taking two medical bio or technology companies to NASDAQ and the New York Stock exchange. Although the company showed up at the last minute, it was able to get one-on-one meetings with all the major investment Banks in attendance, which showed significant interest in what Dr. Hausman is now up to. It was a big success.
Precision Genomics is a leading provider of genomic testing and analysis services. We attended the LD Micro Conference to meet with potential investors and partners. The conference was a big success thanks to our attendance and participation.
Dr. Hausman's experience taking two medical bio or technology companies to NASDAQ and the New York Stock Exchange made him an immediate authority at the conference. His work with Precision Genomics has caught the eye of significant investment banks interested in meeting with him one-on-one to discuss our work. We are confident that these meetings will lead to many future opportunities for Precision Genomics.
Precision Genomics and Ludwig Status Update
Precision Genomics, a Ludwig subsidiary, is an innovative company whose mission is to help people live longer, healthier lives. The company is working diligently to prepare and file an S-1 with the SEC, with the ultimate goal of achieving a listing on NASDAQ. A patent has been filed while the company's research program continues in the hope of delivering potentially life-saving information straight into customers' hands.
Dr. Hausman - Multiple Interviews with Ground Breaking Medical News
Dr. Marvin S. Hausman MD was requested before the event and during the LD Micro conference to do interviews after the company's groundbreaking news announcement about Precision Genomics research into possible diagnosis of Long Covid including potential treatment. Dr. Hausman was featured, during the event, on an LD Micro Spotlight recording. An earlier interview before the event can be seen here, with Rich TV Live: Rich Live TV Interview
About Precision Genomics, a Ludwig Enterprises, Inc. Subsidiary: Advancements in medical technology have awarded us with cutting-edge genetic tools, unheard-of even a generation ago. These genetic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genetic methodology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, preeclampsia, and cancer. This early detection may allow doctors to take steps to diagnose and manage disease before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry billions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig is poised to significantly impact how we think about disease and live longer healthier lives. More Info: http://www.ludwigent.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements are not a guarantee of future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises,
Anne Blackstone,
786-235-9026
www.ludwigent.com
SOURCE: Ludwig Enterprises Inc.
View source version on accesswire.com:
https://www.accesswire.com/724149/Precision-Genomics-Successfully-Attends-the-LD-Micro-Conference
FAQ
What was the outcome of Ludwig Enterprises' attendance at the LD Micro Conference?
What does Precision Genomics focus on?
Who represented Precision Genomics at the LD Micro Conference?
What is Ludwig Enterprises' goal in filing an S-1 with the SEC?
What is the significance of Dr. Hausman's background for Ludwig Enterprises?
